Home › Compound Library › Copper (Bisglycinate)

Copper (Bisglycinate)

Mineraloral · inferred

Essential trace mineral and cofactor for cytochrome c oxidase (mitochondrial respiration), superoxide dismutase (antioxidant defense), lysyl oxidase (collagen/elastin cross-linking), dopamine beta-hydroxylase (catecholamine synthesis), and ceruloplasmin (iron metabolism). Zinc supplementation >25 mg/day induces metallothionein that sequesters copper, causing deficiency over months, so copper co-supplementation is recommended. Absorbed in stomach/duodenum via CTR1 transporter. Excess copper is hepatotoxic.

Projected serum levels — 2 mg, once daily

Copper (Bisglycinate)
Copper (Bisglycinate) modeled serum levels, 2 mg once daily over 121 days Population-based pharmacokinetic estimate. Steady state reached after approximately 91 days. 0 12.5 25 37.5 50 Day 0 Day 30 Day 61 Day 91 Day 121 Time on a regular schedule ≈ steady state · day 91
Copper (Bisglycinate) modeled serum levels with a loading dose of 6 mg, then 2 mg once daily The first dose is larger so levels approach steady state faster. 0 12.5 25 37.5 50 Day 0 Day 30 Day 61 Day 91 Day 121 Time on a regular schedule

Maintenance schedule: 2 mg once daily (oral).

Loading schedule: 6 mg on day 1, then 2 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~91 days: peak ≈ 31.3 mg, trough ≈ 31.0 mg body load. Population-based estimate over 121 days for a 2 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Mineral
Route modeled
Oral
Model confidence
inferred
Half-life
42 days
Common dose
2 mg
Suggested maximum
10 mg/day
Reference dose range
1–10 mg (single dose)
Suggested cadence
once daily

Documented interactions

  • caution
    Alendronate (Fosamax) + Copper (Bisglycinate) Chelation

    Alendronate (Fosamax) (bisphosphonate) forms insoluble complexes with Copper (Bisglycinate) in the GI tract, reducing absorption of both.

  • caution
    Armour Thyroid (Desiccated Thyroid Extract) + Copper (Bisglycinate) Chelation

    Armour Thyroid (Desiccated Thyroid Extract) (thyroid hormone) forms insoluble complexes with Copper (Bisglycinate) in the GI tract, reducing absorption of both.

  • caution
    Ciprofloxacin (Cipro) + Copper (Bisglycinate) Chelation

    Ciprofloxacin (Cipro) (fluoroquinolone antibiotic) forms insoluble complexes with Copper (Bisglycinate) in the GI tract, reducing absorption of both.

  • watch
    CoQ10 (Ubiquinol) + Copper (Bisglycinate) Stacked effects

    Copper (Bisglycinate) and CoQ10 (Ubiquinol) both push the mitochondrial electron transport in the same direction.

  • watch
    2,4-Dinitrophenol (DNP) + Copper (Bisglycinate) Stacked effects

    Copper (Bisglycinate) and 2,4-Dinitrophenol (DNP) both push the mitochondrial electron transport in the same direction.

  • watch
    Methylene Blue + Copper (Bisglycinate) Stacked effects

    Copper (Bisglycinate) and Methylene Blue both push the mitochondrial electron transport in the same direction.

Serum checks 10 modeled interaction pairings for copper (bisglycinate) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination Willis MS et al. · American Journal of Clinical Pathology, 2005 DOI

    Case series documenting zinc-induced copper deficiency presenting as pancytopenia and myelodysplastic features, highlighting the clinical importance of copper supplementation during chronic zinc use.

  2. Copper supplementation and biomarkers of copper status in humans: a systematic review Harvey LJ et al. · American Journal of Clinical Nutrition, 2009 DOI

    Systematic review of 21 studies finding copper supplementation effectively restores copper biomarkers when depleted, with ceruloplasmin and SOD being the most responsive indicators.

  3. Intravenous and oral copper kinetics, biodistribution and dosimetry in healthy humans studied by [64Cu]copper PET/CT. Kjærgaard K, Sandahl TD, Frisch K, Vase KH, Keiding S, Vilstrup H, Ott P, Gormsen LC, Munk OL · EJNMMI radiopharmacy and chemistry, 2020 DOI

    This citation reports a primary research study involving Copper (Bisglycinate). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

3 published studies referenced in the app, each with a plain-language summary.